The patient does not have type 2 diabetes (patients with type 2 diabetes and cardiovascular disease should be considered for Ozempic, which is indicated for this use), and
By focusing on compounded and alternative delivery formats, bmiMD helps reduce costs compared to brand-name GLP-1 medications, which can run over $1,000 per dose without insurance coverage
So the honest answer to the tirzepatide tablet question is nuanced: no approved branded tablet exists, but oral GLP-1 options do, each with its own rules and trade-offs
Building a storage-proof protocol The best storage strategy is one that eliminates opportunities for error
Tirzepatide is a once-weekly, dual-incretin peptide it activates both the GIP and the GLP-1 receptor from a single molecule and in published obesity trials it has produced some of the largest average weight reductions of any incretin agent studied to date
Global Heart 2017, 12: 341-348